Spain Strengthens Biotech and Health Research with Major Investments in 2024-2025

The Instituto de Salud Carlos III (ISCIII) and the Castilla y León region are at the forefront of Spain's recent advances in health research and biotechnology funding. In 2025, ISCIII promoted nearly 300 innovative health projects and maintained close to 100 active patents in translational biomedical research. Director General Marina Pollán emphasized ISCIII's key role over its 40-year history in bridging science and health, stating that their presence at the Foro Transfiere facilitated crucial collaborations between public and private sectors. ISCIII invested €192 million in health research last year, marking an 11% increase from 2024 and underscoring its position as a major scientific engine for the National Health System.

Meanwhile, Castilla y León allocated €82.3 million to biotechnology research in 2024, reinforcing its commitment to sectors like health and agro-food. Though this accounts for 2.6% of Spain’s total €3.144 billion biotechnology investment, the region's model hinges on substantial contributions from public institutions and universities, with €49 million originating from these sources and €32 million from private businesses. While the business sector in Castilla y León still has growth potential, biotechnology across Spain employs around 40,000 people, predominantly women, reflecting the field’s strong social dimension.

Both ISCIII’s focus on translational health research and Castilla y León's commitment to biotech R&D highlight Spain's strategic pursuit of innovation to convert scientific advances into effective health solutions and economic growth. Challenges remain, particularly in enhancing industry participation in the regions, but the combined efforts lay a strong foundation for sustained development in health and biotechnology.